GSK Plus Sanofi: The COVID-19 Vaccine Dream Team?

Tried-And-Tested Platforms Could Pay Off

While not promising the fastest development time that the world craves, the combined experience and scale of the two vaccine giants bodes well.

GSK_HQ
By pooling its expertise and manufacturing scale with rivals Sanofi on the COVID-19 vaccine, GSK is increasing the odds of success

It has taken longer to emerge than the many fast-tracked programs launched in recent months, but GlaxoSmithKline PLC’s decision to work with

Sanofi could prove to be a significant boost to the chances of a broadly effective COVID-19 vaccine emerging in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip